Y. Oba

发表

Y. Oba, 2003, The New England journal of medicine.

High levels of PEEP may improve survival in acute respiratory distress syndrome: A meta-analysis.

Y. Oba, D. Thameem, Tareq Zaza, 2009, Respiratory medicine.

Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.

Y. Oba, 2009, The American journal of managed care.

Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis

S. Dias, Y. Oba, S. Sarva, 2015, Thorax.

Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis

S. Dias, Y. Oba, S. Sarva, 2015, Thorax.

The Prevalence and Diagnostic Significance of Eosinophilic Pleural Effusions: A Meta-Analysis and Systematic Review

Y. Oba, Tareq Abu-Salah, Tareq M. Abu‐Salah, 2011, Respiration.

Pneumonia, Community-Acquired

H. Regunath, Y. Oba, S. Engelberg, 2017 .

Safety, tolerability and risk benefit analysis of tiotropium in COPD

Y. Oba, D. Thameem, Tareq Zaza, 2008, International journal of chronic obstructive pulmonary disease.

Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis

S. Dias, Y. Oba, Sumayya Anwer, 2020, Cochrane Database of Systematic Reviews.

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis.

S. Dias, Y. Oba, Sumayya Anwer, 2020, The Cochrane database of systematic reviews.

Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.

Y. Oba, 2009, JAMA.

Reevaluation of continuous oxygen therapy after initial prescription in patients with chronic obstructive pulmonary disease.

S. Willsie, Y. Oba, G. Salzman, 2000, Respiratory care.

Hospitalizations with severe COPD.

Y. Oba, 2007, American journal of respiratory and critical care medicine.

Management of Chronic Obstructive Pulmonary Disease: Review Questions

Y. Oba, 2004 .

Does tiotropium reduce hospitalizations in chronic obstructive pulmonary disease?

Y. Oba, 2008, Annals of internal medicine.

Cost-effectiveness of long-term oxygen therapy for chronic obstructive disease.

Y. Oba, 2009, The American journal of managed care.

Tiotropium versus salmeterol in COPD.

Y. Oba, 2011, The New England journal of medicine.

Cardiovascular safety of roflumilast.

Y. Oba, N. Lone, 2013, Chest.

Where are the institutional review boards?

Y. Oba, 2002, American journal of respiratory and critical care medicine.

Positioning of Prone Ventilation in the Management of Acute Respiratory Distress is

Y. Oba, 2013 .

Reply to On the need for competent evaluation of trial quality

Y. Oba, 2012 .

Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.

S. Dias, Y. Oba, E. Keeney, 2018, The Cochrane database of systematic reviews.

Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis

Y. Oba, N. Lone, N. Lone, 2014, International journal of chronic obstructive pulmonary disease.

Efficacy and safety of long-acting-agonist/long-acting muscarinic antagonist combinations in COPD: a network

S. Dias, Y. Oba, S. Sarva, 2015 .

Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

Y. Oba, N. Lone, 2013, Therapeutic advances in respiratory disease.

Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis

Y. Oba, Arul Chandran, J. Devasahayam, 2016, COPD.

Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression

Y. Oba, N. Lone, N. Lone, 2015, Therapeutic advances in respiratory disease.

Roflumilast: a green signal is yet to come.

Y. Oba, N. Lone, 2013, Journal of thoracic disease.

A case of acute non-typeable Hemophilus influenza infective endocarditis in a patient with hypocomplementemia

Y. Oba, S. Patil, Delvise T. Fogwe, 2023, IDCases.

Mortality benefit of vasopressor and inotropic agents in septic shock: a Bayesian network meta-analysis of randomized controlled trials.

Y. Oba, N. Lone, 2014, Journal of critical care.

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma.

Y. Oba, G. Salzman, 2004, The Journal of allergy and clinical immunology.

Phosphodiesterase inhibitors in chronic obstructive pulmonary disease.

Y. Oba, 2013, American journal of respiratory and critical care medicine.

Fixed-dose combination inhalers compared to long-acting bronchodilators for COPD: a network meta-analysis

S. Dias, Y. Oba, E. Keeney, 2017 .

Y. Oba, Sumayya Anwer, T. Maduke, 2023, The Cochrane database of systematic reviews.

Abandoning daily routine chest radiography in the intensive care unit: meta-analysis.

Y. Oba, Tareq Zaza, 2010, Radiology.

Data Collection Issues With Mortality Risk of Inhaled Corticosteroids in COPD.

Y. Oba, 2023, Chest.

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury.

Y. Oba, G. Salzman, 2000, The New England journal of medicine.

(2016). Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax, 71(1), 15-25

Y. Oba, S. Sarva, Sofia Dias, 2015 .

The Prevalence and Diagnostic Significance of Eosinophilic Pleural Effusions: A Meta-Analysis and Systematic Review

Y. Oba, Tareq M. Abu‐Salah, 2011, Respiration.